Cannabis Central: Pot Stocks Took A Belated Holiday Wednesday Going Up Only 1.2%

Only 12 of the 39 NPSI constituents advanced while 27 declined. 3 stocks advanced more than 5% (Pyxus International was up the most at 21.3%) while 4 declined by 5% or more (Zynerba Pharmaceuticals was down the most at 9.7%).

The Non-Penny Pot Stock Index (NPSI) was more or less flat on Wednesday up a meager 1.2% on the day. Pyxus advanced the most (21.3%) while Zynerba declined the most (-9.7%).

Only 12 of the 39 NPSI constituents (pot stocks that trade for US$1/share or more) advanced while 27 declined. Only 3 stocks advanced more than 5% while 4 declined by 5% or more. Here are the details:

The Biggest Winners 

  • 1 constituent advanced +20%:
    • Pyxus (PYX) +21.3% 
  • 2 constituents advanced between 5% and 19.9%: 
    • Greenlane (GNLN) +6.7%
    • GrowGeneration (GRWG) +6.2%

The Biggest Losers

  • Zynerba (ZYNE) -9.7%
  • Abacus (ABAHF) -9.2%
  • Charlotte's Web (CWBHF) -8.8%
  • New Age (NBEV) -5.5%

Notable Mention: HEXO (HEXO) -2.7% (a former constituent but now trading below US$1/share.)

Further details regarding the constituents of the NPSI are as follows:

  • 2 trade above US$20/share,
  • 6 trade between US$10 and US$20/share,
  • 10 trade between US$5 and US$10/share and
  • 21 trade between US$1 and US$5/share. (The official definition of a "penny" stock is one that trades below US$5/share but, when it comes to pot stocks, that is where 88% of the total universe trades, so the more literal definition of stocks that trade for less than US$1/share is used.)

The market capitalization makeup of the NPSI (calculated by multiplying the number of a company's shares outstanding by its stock price per share, is as follows:

  • Large-Cap (+US$10B): 0
  • Mid-Cap (US$2B to US$10B): 3
  • Small-Cap (US$300M to US$2B): 13
  • Micro-Cap (US$50M to US$300M): 19
  • Nano-Cap (Less than US$50M): 4

To see how the new Non-penny Pot Stock Index (NPSI) has done on a daily basis recently, visit the daily updates here.

STOCKS IN THIS ARTICLE

Comments